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Aberrant glycosylation in IgA nephropathy (IgAN). Im-
munoglobulin A nephropathy (IgAN) patients exhibit circu-
lating IgA1 with reduced galactose (Gal) and/or sialic acid
(Neu5Ac) and increased exposure of N-acetylgalactosamine
(GalNAc). These IgA glycoforms fix complement and in mesan-
gial cells regulate integrin expression, enhance nitric oxide
synthase (NOS) activity, decrease endothelial growth factor
synthesis, meanwhile depressing proliferation and increasing
apoptotis. Drugs can be targeted to the effects enhanced by
aberrantly glycosylated IgA1 on mesangial cells. Recent data
suggest that aberrant IgA1 glycosylation may modulate clinical
expression and progression of IgAN.
Immunoglobulin A nephropathy (IgAN) is defined
by prevalent mesangial deposits of IgA, proliferation of
mesangial cells, and expansion of matrix, ultimately lead-
ing to glomerular sclerosis [1]. The formation of mesan-
gial deposits was initially ascribed to accumulation of IgA
immune complexes (IgAIC) [2]. However, this hypoth-
esis was not supported by the searches for alimentary
or viral antigens in circulating IgAIC or renal deposits
that were inconclusive. The qualitative properties of poly-
meric IgA1, which constitute the mesangial deposits, have
rather become of interest, particularly the glycosylation
pattern of IgA1.
GLYCOSYLATION OF IgA1 IN HEALTHY
SUBJECTS AND IN PATIENTS WITH IgAN
Human IgA1 is O-glycosylated, which is unusual
for serum proteins [2, 3] (Fig. 1). The O-glycans, lo-
cated in the IgA1 hinge region, are based on a core
N-acetylgalactosamine (GalNAc) linked to serine and/
or threonine residues of the amino acidic backbone
and usually extended with galactose (Gal) to form
Galb1,3GalNAc, which may be covered with a 2,6 and/or
a 2,3 sialic acid (Neu5Ac). Thus, each IgA1 O-glycan may
have one or four short carbohydrate structures, leading
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to a mixture of IgA1 glycoforms provided with varying
degrees of galactosylation and sialylation.
We observed that the binding of serum IgA from
IgAN patients to a wide variety of molecules (exoge-
nous alimentary antigens or endogenous mesangial com-
ponents) was based upon carbohydrate interactions,
regardless of antigen specificity [5, 6]. Some authors, in-
cluding ourselves, have then demonstrated that in IgAN
the O-glycosylation pattern of serum IgA1 is abnormal,
with reduced galactose and/or sialic acid content, leading
to increased exposure of the internal GalNAc. Gal defi-
ciency was demonstrated by higher binding to GalNAc-
specific lectins [7, 8] or increased asialo-Galb1,3GalNAc
residues detected by mass spectrometry [9]. We used an-
other approach to investigate the glycosylation pattern
of serum IgA. Different glycoforms of IgA were isolated
in sera from IgAN patients and controls by affinity chro-
matography using lectin columns [10]. The eluted peaks
were fractionated in high-performance liquid chromatog-
raphy (HPLC) to isolate 250 to 400 kD glycoproteins
and the IgA content measured. IgAN patients showed,
in comparison to healthy controls, increased IgA glyco-
forms with greater exposure of GalNAc and Neu5Ac-
a2,6GalNAc. Incomplete galactosylation of O-linked gly-
cans in the IgA1 hinge region results in the exposure
of underlying neoantigenic GalNAc that was found to
be recognized by naturally occurring antibodies (IgG or
IgA1 specific for GalNAc) [11] or in IgA1-IgA1 interac-
tions [12].
The pathogenetic role of aberrantly glycosylated IgA1
(AGlyIgA1) was confirmed by its detection in mesangial
deposits of IgAN patients either by binding to specific
lectins or mass spectrometry [13]. Moreover, enzymati-
cally deglycosylated IgA1 was proved to induce glomeru-
lar inflammation in rats [14].
INTERACTION OF ABERRANTLY
GLYCOSYLATED IgA WITH
MESANGIAL CELLS
Understanding the mechanism by which macro-
molecules containing IgA1 bind to mesangial cells and
the effects produced by this binding is of utmost rele-
vance. IgA1 molecules deficient in Gal and/or sialic acid,
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Fig. 1. Glycosylation of aberrantly glycosy-
lated (IgA1) molecule.
as IgA1-IgA1IC or IgG-IgA1IC, or combined with ex-
ogenous antigens in IgA1IC, are likely to escape the
hepatic catabolism [15] and, by virtue of enhanced car-
bohydrate interactions with fibronectin, laminin, and col-
lagen of mesangial matrix [6], undergo a preferential
deposition in the mesangial area. Mesangial cells bind
asialo-agalacto IgA1 more efficiently that normally gly-
cosylated IgA1 [15]. Circulating IC (CIC) from IgAN
patients bind to mesangial cells even more efficiently
than AGlyIgA1, suggesting that CIC can interact with
mesangial cells in a more complex manner possibly in-
volving other immunoglobulin or complement receptors.
The IgA receptors on mesangial cells do not exhibit prop-
erties of FcaR (CD89) or asialoglycoprotein receptors
(ASGP-R) [15] and possibly belong to the transferrin re-
ceptor family [16].
Over the last years we focused particular atten-
tion on the modulation of mesangial cell reactivity
by AGlyIgA, investigating the biologic effects of se-
lected glycoforms from IgAN patients rich in terminal
GalNAc or Neu5Ac2,6,GalNAc and in vitro deglycosy-
lated IgA obtained by treating normal IgA with neu-
raminidase, desialylated (deSia) IgA, or neuraminidase
and b-galactosidase (b-Gal) (deSia/deGal) IgA [17].
Complement is a crucial mediator in experimental
models of IgAN and deglycosylated IgA have increased
C3b fixation. By using a monoclonal antibody directed
against a neoepitope on activated C3 (C3b, iC3b, C3dg),
we found that GalNAc and Gal exposing glycoforms iso-
lated form IgAN patients were significantly more active
for complement activation than controls [17].
We investigated the modulation of mesangial cell inte-
grins by AGlyIgA (Fig. 2) [18]. Signal transduction by
mesangial cell integrins regulates cell growth and sur-
vival, matrix production and organization. In vitro pre-
pared deSia IgA and deSia/deGal IgA enhanced avb3
expression on cultured mesangial cells as well as IgA from
IgAN patients with high exposure of internal sugars.
To gain insight into the glomerular capillary repair in
IgAN we focused on vascular endothelial growth factor
(VEGF)-A and nitric oxide modulation [19]. We demon-
strated a down-regulation of VEGF-A mRNA transcrip-
tion and protein synthesis in mesangial cells incubated
with in vitro prepared AGlyIgA and with IgA glycoforms
isolated from IgAN patients. Conversely, deSia IgA and
even more deSia/deGal IgA significantly up-regulated
ntric oxide synthase (NOS) activity of mesangial cells
with enhancement of inducible NOS (iNOS) mRNA tran-
scription. AGlyIgA isolated from sera of IgAN patients,
particularly IgA bearing Neu5-2,6,GalNAc residues, sim-
ilarly depressed VEGF-A production and enhanced NOS
activity and iNOS mRNA transcription. The depression
of the VEGF-A production was mediated by nitric oxide,
since it was blunted by NOS-specific inhibitors.
Moreover, we observed that AGlyIgA, either the in
vitro prepared deSia IgA and deSia/deGal IgA and
the IgA glycoforms from IgAN patients expressing
GalNAc or Neu5Ac-2,6,GalNAc, significantly depressed
the mesangial cell proliferation rate and enhanced apop-
tosis [10].
AGlyIgA prepared in vitro as well as IgA glycoforms
isolated from IgAN patients were able to fix complement,
modulate in mesangial cell integrin expression, enhance
NOS activity, and decrease VEGF-A synthesis, mean-
while depressing cell proliferation and increasing the
apoptotic rate (Fig. 2). Of interest, while we observed the
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Fig. 2. Biologic effects on cultured human mesangial cells of selected glycoforms isolated from sera of immunoglobulin A nephropathy (IgAN)
patients and healthy controls. The figure shows the modulation induced by IgA exposing terminal N-acetylgalactosamine (GalNAc) or a2,3 sialic
acid (Neu5Ac)2,6,GalNAc on (A) av integrin chain [18], (B) nitric oxide synthase (NOS) activity [19], (C) proliferation rate, and (D) apoptosis
[10].
antiproliferative effect induced by serum macromolec-
ular fractions with molecular weight of 200 to 450 kD,
high molecular weight CIC (700 to 1000 kD) were found
to enhance mesangial cell proliferation [abstract; Novak
et al, Nephrol Dial Transplant 18:A13, 2003]. IgAN is a
renal disease characterized by mesangial cell prolifera-
tive changes, which leave place to sclerotic lesions during
the progression. CIC molecular weight is likely to be a
crucial factor in modulating mesangial cell proliferation.
ABERRANT GLYCOSYLATION OF SERUM
IgA1 AND DISEASE EXPRESSION
AND PROGRESSION
Why some IgAN progress to end-stage renal failure
and recur in the grafted kidney while others have a benign
course is still unknown.
We investigated the levels of IgA1 binding to Vicia vil-
losa and Helix aspersa (provided with slightly different
GalNAc specificity) in transplanted IgAN with or with-
out recurrence [abstract; Chiesa et al, J am Soc Nephrol
13:180A, 2002]. These patients with original progressive
IgAN had significantly higher levels of GalNAc exposing
IgA1 (binding to V. villosa and H. aspersa) than controls.
The levels of IgA1 binding to V. villosa were significantly
higher in recurrent than in non recurrent patients, and this
property was of predictive value for recurrence of IgAN.
No difference in IgA1 binding to H. aspersa was detected
between recurrent and nonrecurrent patients. In another
cohort of IgAN patients, with normal renal function and
proteinuria, levels of IgA1 binding to V. villosa were sim-
ilar to controls, while IgA1 binding to H. aspersa were sig-
nificantly higher. Heterogeneity of O-glycosylation in the
hinge region of IgA1 has been detected in patients and
in healthy controls [20]. Selected lectin binding capaci-
ties were reported in correlation with glomerular base-
ment membrane (GBM) thickness [21]. In conclusions, it
is tempting to speculate that different defects in IgA1 gly-
cosylation might influence presentation and natural his-
tory of single cases. Further follow-up studies are needed
to investigate whether the carbohydrate pattern of IgA1
is constant or may change over time.
We and others have reported AGlyIgA1 in Henoch-
Schoenlein purpura IgAN (HSP) [22]. The two condi-
tions mostly differ as systemic vasculitic involvement.
We demonstrated that endothelial cells interact with
AGlyIgA with activation of iNOS and release of toxic
amount of nitric oxide, potentially harmful for vascu-
lar walls. Moreover, IgA binding to lysosomal enzymes
[(IgA-anitneutrophil cytoplasmic antibodies (ANCA)]
have been reported in patients with HSP nephritis by us
and by several investigators. We demonstrated that this
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property depends upon an abnormal carbohydrate inter-
action between AGlyIgA and the lysosomal glycopro-
teins [22]. Differences in degree, extent or kind of IgA1
glycosylation likely modulate the expression of IgAN
with or without the features of a systemic vasculitis.
NEW INSIGHT INTO DRUG REGULATION
OF THE EFFECTS OF ABERRANTLY
GLYCOSYLATED
We observed that several biologic effects of AGlyIgA1
on mesangial cells are mediated by the activation of the
transcriptional factor nuclear factor-jB (NF-kB). It is
known that specific stimuli dissociate the complex be-
tween the inhibitory protein IkB and the active NF-kB
subunits with nuclear translocation of the latter initiat-
ing the transcription of proinflammatory and prosclerotic
mediators. The cytoplasmic IkB level available for bind-
ing and inactivating NF-kB is regulated by the protea-
somes, which degrade ubiquitinated IkB. Mesangial cells
treated with AGlyIgA showed the nuclear translocation
of NF-kB, in parallel with reduction in IkB levels, due
to proteasome inactivation. This event and the related
biologic effects were blunted by coincubation with an-
giotensin antagonists [abstract; Chiesa et al, J Am Soc
Nephrol 13:494A, 2002]. The modulation of proteasome
activity could represent a new way to limit the biologic
effects induced on mesangial cells by AGlyIgA1.
CONCLUSION
A derangement in IgA1 glycosylation characterize cir-
culating and deposited IgA in IgAN. Aberrant IgA gly-
coforms are biologically active in cultured renal cells
mostly enhancing the synthesis of NF-kB–dependent me-
diators. Search of effective therapies can be targeted on
the control of the effects enhanced in mesangial cells by
AGlyIgA1. Further investigations are needed to confirm
the value of AGlyIgA in modulating clinical expression
and evolution of IgAN.
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